HRTX
Heron Therapeuti
0.3476$
-2.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.2% | 97.8% | 92.1% | 97.3% | 96.8% | 93.4% | 88.9% | 83.2% | 81.9% | 84.8% | 89.6% | 93.0% | |
| 94.8% | 54.5% | 19.9% | 61.7% | 6.9% | 14.0% | 29.7% | 29.6% | 6.1% | 12.9% | 11.1% | 11.2% | |
| 94.8% | 95.2% | 75.8% | 73.6% | 71.9% | 76.2% | 59.0% | 51.5% | 33.8% | 36.1% | 25.4% | 18.2% | |
| – | 0.0% | 2.9% | 17.9% | 14.0% | 7.8% | 11.8% | 11.6% | 20.7% | 27.0% | 33.8% | 35.0% | |
| 0.0% | 0.0% | 7.9% | 4.3% | 8.4% | 4.9% | 11.9% | 15.8% | 21.7% | 18.9% | 22.8% | 36.2% | |
| 3.7% | 2.2% | 7.5% | 2.6% | 3.2% | 3.8% | 6.4% | 11.0% | 11.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 17.8% | 14.3% | 131.5% | 44.0% | 19.9% | 21.2% | 33.1% | 74.6% | 94.6% | 115.3% | 114.4% | 94.4% | |
| 17.8% | 14.3% | 57.4% | 44.0% | 19.9% | 18.9% | 29.0% | 23.2% | 32.8% | 35.8% | 39.2% | 37.6% | |
| 2.1% | 1.6% | 4.3% | 12.2% | 1.0% | 1.5% | 2.8% | 0.8% | 1.1% | 1.4% | 1.3% | – | |
| 3.3% | 2.4% | 10.1% | 8.0% | 3.6% | 0.6% | 0.2% | 1.3% | 1.4% | 1.7% | 5.0% | 3.5% | |
| 0.0% | 0.0% | 74.1% | 0.0% | – | – | – | 48.8% | 59.5% | 78.1% | 74.9% | 55.0% | |
| 82.2% | 85.7% | -31.5% | 56.0% | 80.1% | 78.8% | 66.9% | 25.4% | 5.4% | -15.3% | -14.4% | 5.6% | |
| -411.1% | -299.5% | -868.3% | -334.4% | -207.9% | -227.3% | -393.9% | -527.8% | -715.5% | -856.6% | -823.3% | -758.1% | |
| 34.6% | 24.0% | 56.2% | 23.1% | 15.8% | 15.9% | 25.7% | 32.2% | 43.4% | 62.1% | 65.4% | 65.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.